Funding for this research was provided by:
National Cancer Institute (K08 CA207882)
U.S. National Library of Medicine (GM 102365)
Text and Data Mining valid from 2019-10-14
Received: 22 February 2019
Accepted: 9 September 2019
First Online: 14 October 2019
: A.A.A. declares the following competing interests: stock or other ownership (CiberMed and Forty Seven); honoraria (Janssen Oncology); consulting or advisory roles (Celgene, Roche/Genentech and Gilead Sciences); research funding (Celgene); patents, royalties or other intellectual property (patent filings on immune deconvolution and circulating tumor DNA detection assigned to Stanford University); and travel, accommodations or expenses (Roche and Gilead Sciences). R.B.A. declares the following competing interests: stock or other ownership (Personalis); consulting or advisory role (Pfizer, Youscript, 23andme and WithHealth); patents, royalties or other intellectual property (royalties for patents related to genome sequencing).